Management Q&A: View from the Top

Medical Use of Nitric Oxide Expands as Costs Come Down

Managment Q&A: View from the Top
  ()
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. read more >

Cancer Vaccine Developer Expands Its Collaboration with Merck

Research Report
  ()
A Mackie Research Capital report tells how this biotech will benefit from its new and existing programs with this specific partner. read more >

Coverage Initiated on 'Emerging Antibiotics Growth Story with Multiple Levers for Upside'

Research Report
  ()
An H.C. Wainwright & Co. report outlined the investment thesis for this U.S.-based biopharmaceutical firm. read more >
News Update

U.S. Biotech Partner Obtains Marketing Authorization for ADHD Treatment in Taiwan

News Update
  ()
Permission has been obtained to distribute time-release capsules. read more >

Why Tiny ITUS's CAR-T Therapy Could Be a Big Deal in Cancer Treatment

Contributed Opinion
  ()
With CAR-T being the hottest space in cancer therapy, Daniel Carlson of Tailwinds Research profiles an innovative company that has been collaborating with a major cancer center. read more >

Canadian Biopharma to Outlicense Pain Drug to South Korean Firm

Research Report
  ()
An Echelon Wealth Partners report discussed the deal terms. read more >

Biopharma's Positive FDA Meeting Outlines Path Forward for Trial

Research Report
  ()
A ROTH Capital Partners note explained the outcome of the tête-a-tête and its implications. read more >

Final Approval of Biopharma's Lead Candidate Both Likely and Imminent

Research Report
  ()
A ROTH Capital Partners report provided the takeaways from a recent meeting with the management team for this company, which is targeting an orphan indication. read more >

Coverage Initiated on Firm with Paradigm-Shifting Colonoscopy Device

Research Report
  ()
A Ladenburg Thalmann report covered the asset, product market and financial projections of this Florida-based company. read more >
News Update

Drug Company Receives $5 Million Milestone Payment

News Update
  ()
Company entitled to receive quarterly earn-out payments from patent agreement. read more >
Expert Investing Ideas

"PMN anticipates launching its first in-human trial in 2019 of PMN310."

–John Vandermosten, Zacks Small-Cap Research


"DRRX's total revenue for Q2/18 was $3.4M."

–Grant Zeng, Zacks Small-Cap Research


"We consider DRRX a development story."

–Francois Brisebois, Laidlaw & Company


"We are initiating coverage on PMN."

–John Vandermosten, Zacks Small-Cap Research


"DRRX reported its Q1/18, mostly in line with expectations."

–Francois Brisebois, Laidlaw & Company


"PMN is seeking to forge partnerships with big pharmas."

–André Uddin, Mackie Research Capital


Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe
NASDAQ Biotech ARCA Pharmaceutical
News Update

Neurosciences Company Reports Potential for Improved Safety Profile for Alzheimer's Treatment

News Update
  ()
The substance shows potential for an improved safety profile in direct comparison to other Amyloid Beta-Directed Antibodies in clinical development. read more >

Investor Opportunity Arises from Biopharma's Share Price Weakness on Competitor News

Research Report
  ()
An analyst discussed the implications to this firm of a competitive product's advancement. read more >

Oncology-Focused Biotech Receives Orphan Status for AML Drug

Research Report
  ()
An H.C. Wainwright & Co. report provided an update on two of this company's four product candidates. read more >
News Update

As Nitric Oxide Comes Off Patent, Lower-Cost Options for Life Saving Drug Becoming Possible

  ()
Dr. Ronald Day, a pediatric cardiologist at the University of Utah, has been using nitric oxide to treat children with pulmonary hypertension. Now, with a court ruling invalidating much of a drug patent for nitric oxide, lower-cost options might become available. read more >